FTSE MIB
33.817,43 +663,38 (+2,00%) Dow Jones
39.118,86 -45,24 (-0,12%) Nasdaq
17.732,60 -126,10 (-0,71%) Nikkei 225
39.631,06 +47,98 (+0,12%) Petrolio
82,17 +0,63 (+0,77%) Bitcoin EUR
58.810,46 +1.596,29 (+2,79%)
Novartis AG (NOVNN.MX)
| Chiusura precedente | 1.719,29 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Domanda | 0,00 x N/D |
| Min-Max giorno | 1.719,29 - 1.719,29 |
| Intervallo di 52 settimane | 1.719,29 - 1.719,29 |
| Volume | |
| Media Volume | 50 |
| Capitalizzazione | N/D |
| Beta (mensile su 5 anni) | 0,50 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 18 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireNovartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan) in the pre-chemotherapy setting for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) New analysis of key subgroups of clinical interest from NATALEE reinforces the potential of Kisqali® (ribociclib) plus endocrine therapy (ET) to consistently reduce the risk of cancer recurrence across a broa
- GlobeNewswire
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-offShares of Sandoz will be listed and commence trading today on the SIX Swiss ExchangeSpin-off allows shareholders to benefit from a Novartis with capital and management attention fully focused on innovative medicinesNovartis pipeline one of the industry’s most competitive, focused on key next-generation platforms and four core therapeutic areasCo
- GlobeNewswire
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria reduction1 Iptacopan is an investigational, first-in-class, oral factor B inhibitor targeting the alternative pathway of the complement system2–4 IgAN is a complement-mediated kidney disease, affects mostly young adults, and is a major cause of chronic kidney disease and kidney failure worldwide5–9 Novar
